Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 2/20 | 0.36 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 2/20 | 0.36 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | TP53 | P04637 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.33 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.33 |
| ▸ | RELA | Q04206 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5503543 | 0.69 | CYP1A2 (0.69) | POLBCYP1A2KMT2AMEN1SMN1; SMN2 | |
| SCHEMBL14058963 | 0.64 | ALDH1A1 (0.38) | POLBCYP1A2NPC1RAB9AKMT2A | |
| SCHEMBL27554600 | 0.59 | — | — | |
| SCHEMBL1001732 | 0.55 | HDAC2 (0.33) | NPC1RAB9A | |
| SCHEMBL6823115 | 0.53 | RAB9A (0.34) | POLBNPC1RAB9AKMT2AMEN1 | |
| SCHEMBL36897 | 0.50 | ALDH1A1 (0.45) | POLBCYP1A2SMN1; SMN2TP53 | |
| SCHEMBL190346 | 0.49 | — | — | |
| SCHEMBL11574505 | 0.49 | ALDH1A1 (0.43) | POLBCYP1A2SMN1; SMN2TP53 | |
| Hydrochloric Acid SCHEMBL11203129 | 0.49 | ALDH1A1 (0.43) | POLBCYP1A2KMT2AMEN1SMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL7231265 | 0.49 | ALDH1A1 (0.43) | POLBCYP1A2KMT2AMEN1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120323001-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2012-12-20 | — | — | US | disclosed |
| US-8278441-B2 | BACE inhibitors | ELI LILLY AND COMPANY (US) | 2012-10-02 | — | — | US | disclosed |
| US-20110009395-A1 | BACE INHIBITORS | ELI LILLY AND COMPANY (US) | 2011-01-13 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120323001-A1 | BACE INHIBITORS | BACE1, BACE2, APP | POLB 349/4885CYP1A2 1227/4885NPC1 13/4885 |
| US-20110009395-A1 | BACE INHIBITORS | BACE1, BACE2, APP | POLB 349/4885CYP1A2 1227/4885NPC1 13/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.